{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:34:39Z","timestamp":1770755679373,"version":"3.50.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Although clinical outcomes in chronic lymphocytic leukemia (CLL) have greatly improved with several approved small molecular inhibitors, acquired resistance does occur, leading to disease progression and eventual death. Thus, the effort to explore novel inhibitors and combination therapeutic regimens is needed. The inhibition of MDM2-p53 interaction to restore p53 function has been regarded as a potential strategy for treating different cancers. We investigated the effects of novel MDM2 inhibitor APG-115 in CLL. We found that APG-115 treatment upregulated the expression of p53, MDM2, and p21 at the mRNA and protein level. APG-115 inhibited cell proliferation, induced apoptosis, and arrested the cell cycle at G0\/G1 stage. Moreover, APG-115 inhibited the expression of BCL-2, BCL-xL, and MCL-1, and suppressed the activation of AKT and ERK signaling pathways. APG-115 combined with the BCL2 inhibitor, ABT-199 (venetoclax), led to further inhibition of the expression of BCL-2 family anti-apoptotic proteins and consequently enhanced cell death. Collectively, this study demonstrates that APG-115 activates p53 and thus inhibits multiple pro-survival mechanisms, which provides a rational explanation for APG-115 efficiency in inducing cell apoptosis in CLL. The synergistic effect of APG-115 with ABT-199 suggested a potential combination application in CLL therapy.<\/jats:p>","DOI":"10.3389\/fphar.2024.1441383","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T04:22:41Z","timestamp":1722399761000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["MDM2 inhibitor APG-115 synergizes with ABT-199 to induce cell apoptosis in chronic lymphocytic leukemia"],"prefix":"10.3389","volume":"15","author":[{"given":"Ying","family":"Cui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoya","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyi","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanyue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guomin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqiong","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1021\/acs.jmedchem.6b01665","article-title":"Discovery of 4-((3'R,4'S,5'R)-6\u2033-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2\u2033-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3\u2033-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic acid (AA-115\/APG-115): a potent and orally active murine double minute 2 (MDM2) inhibitor in clinical development","volume":"60","author":"Aguilar","year":"2017","journal-title":"J. Med. Chem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.semcancer.2022.01.009","article-title":"Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia","volume":"84","author":"Albi","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","article-title":"Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia","volume":"22","author":"Andreeff","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"118688","DOI":"10.1016\/j.bbamcr.2020.118688","article-title":"Targeting apoptotic caspases in cancer","volume":"1867","author":"Boice","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia","volume":"21","author":"Cervantes-Gomez","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/bjh.14285","article-title":"Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia","volume":"175","author":"Chen","year":"2016","journal-title":"Br. J. Haematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bjh.15197","article-title":"Differential activation of pro-survival pathways in response to CD40LG\/IL4 stimulation in chronic lymphocytic leukaemia cells","volume":"184","author":"Chen","year":"2019","journal-title":"Br. J. Haematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1182\/blood.v91.11.4342.411k39_4342_4349","article-title":"p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis","volume":"91","author":"Cordone","year":"1998","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41420-021-00465-5","article-title":"MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models","volume":"7","author":"Fang","year":"2021","journal-title":"Cell Death Discov."},{"key":"B11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s40425-019-0750-6","article-title":"MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment","volume":"7","author":"Fang","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1073\/pnas.88.12.5413","article-title":"p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia","volume":"88","author":"Gaidano","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B13","doi-asserted-by":"publisher","first-page":"mjac074","DOI":"10.1093\/jmcb\/mjac074","article-title":"The ARTS of p53-dependent mitochondrial apoptosis","volume":"14","author":"Hao","year":"2023","journal-title":"J. Mol. Cell Biol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/387296a0","article-title":"Mdm2 promotes the rapid degradation of p53","volume":"387","author":"Haupt","year":"1997","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/ejh.12756","article-title":"Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388)","volume":"97","author":"Herting","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1158\/1078-0432.CCR-14-2506","article-title":"Elucidation of acquired resistance to bcl-2 and MDM2 inhibitors in acute leukemia in vitro and in vivo","volume":"21","author":"Hoffman-Luca","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s0014-5793(97)01480-4","article-title":"Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53","volume":"420","author":"Honda","year":"1997","journal-title":"FEBS Lett."},{"key":"B18","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41419-020-03144-y","article-title":"Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance","volume":"11","author":"Kapoor","year":"2020","journal-title":"Cell Death Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/BF02982115","article-title":"Activation of extracellular signal-regulated kinase through B-cell antigen receptor in B-cell chronic lymphocytic leukemia","volume":"75","author":"Kawauchi","year":"2002","journal-title":"Int. J. Hematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/PPO.0000000000000406","article-title":"Resistance mechanisms to targeted agents in chronic lymphocytic leukemia","volume":"25","author":"Kittai","year":"2019","journal-title":"Cancer J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1182\/blood-2005-12-5148","article-title":"Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia","volume":"108","author":"Kojima","year":"2006","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1158\/0008-5472.CAN-06-2712","article-title":"Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells","volume":"67","author":"Kojima","year":"2007","journal-title":"Cancer Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1038\/leu.2008.158","article-title":"The dual PI3 kinase\/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML","volume":"22","author":"Kojima","year":"2008","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"53968","DOI":"10.18632\/oncotarget.16345","article-title":"MDM2 antagonists synergize with PI3K\/mTOR inhibition in well-differentiated\/dedifferentiated liposarcomas","volume":"8","author":"Laroche","year":"2017","journal-title":"Oncotarget"},{"key":"B26","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/jpm11060463","article-title":"Review of venetoclax in CLL, AML and multiple myeloma","volume":"11","author":"Lasica","year":"2021","journal-title":"J. Pers. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-016-0280-3","article-title":"Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models","volume":"9","author":"Lehmann","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1005659","DOI":"10.3389\/fonc.2022.1005659","article-title":"Mechanisms of venetoclax resistance and solutions","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"B30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3727\/096504020X15825405463920","article-title":"A novel BCL-2 inhibitor APG-2575 exerts synthetic lethality with BTK or MDM2-p53 inhibitor in diffuse large B-cell lymphoma","volume":"28","author":"Luo","year":"2020","journal-title":"Oncol. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"490","DOI":"10.18632\/aging.100047","article-title":"The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway","volume":"1","author":"Maclaine","year":"2009","journal-title":"Aging (Albany NY)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.ccell.2017.11.003","article-title":"Synthetic lethality of combined bcl-2 inhibition and p53 activation in AML: mechanisms and superior antileukemic efficacy","volume":"32","author":"Pan","year":"2017","journal-title":"Cancer Cell"},{"key":"B33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1756-8722-6-83","article-title":"Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application","volume":"6","author":"Pozzo","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2017-10-809020","article-title":"Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL","volume":"132","author":"Reiff","year":"2018","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1182\/blood-2002-02-0539","article-title":"Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta","volume":"100","author":"Ringshausen","year":"2002","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"775761","DOI":"10.3389\/fimmu.2021.775761","article-title":"Improving immunotherapy efficacy in soft-tissue sarcomas: a biomarker driven and histotype tailored review","volume":"12","author":"Roulleaux Dugage","year":"2021","journal-title":"Front. Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1182\/blood-2007-09-112698","article-title":"Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia","volume":"111","author":"Saddler","year":"2008","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"936","DOI":"10.4161\/cbt.9.11.11882","article-title":"MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity","volume":"9","author":"Saha","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"6311","DOI":"10.1158\/0008-5472.CAN-16-0843","article-title":"Posttranscriptional upregulation of p53 by reactive oxygen species in chronic lymphocytic leukemia","volume":"76","author":"Samuel","year":"2016","journal-title":"Cancer Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/0092-8674(90)90409-8","article-title":"The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53","volume":"63","author":"Scheffner","year":"1990","journal-title":"Cell"},{"key":"B42","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: a review","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"key":"B43","doi-asserted-by":"publisher","first-page":"5318","DOI":"10.1158\/1078-0432.CCR-07-5136","article-title":"Targeting the MDM2-p53 interaction for cancer therapy","volume":"14","author":"Shangary","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-017-0500-5","article-title":"MDM2\/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer","volume":"10","author":"Tisato","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/humu.10178","article-title":"The role of TP53 in Cervical carcinogenesis","volume":"21","author":"Tommasino","year":"2003","journal-title":"Hum. Mutat."},{"key":"B46","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1182\/blood-2008-08-173310","article-title":"Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia","volume":"113","author":"Vogler","year":"2009","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1182\/blood.v84.9.3158.3158","article-title":"The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin","volume":"84","author":"Watanabe","year":"1994","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1182\/blood-2013-07-515361","article-title":"Bruton\u2019s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)","volume":"123","author":"Woyach","year":"2014","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13046-018-0765-8","article-title":"A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma","volume":"37","author":"Yi","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1158\/1078-0432.CCR-22-0978","article-title":"Lisaftoclax in combination with alrizomadlin overcomes venetoclax resistance in acute myeloid leukemia and acute lymphoblastic leukemia: preclinical studies","volume":"29","author":"Zhai","year":"2023","journal-title":"Clin. Cancer Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1441383\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T04:22:44Z","timestamp":1722399764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1441383\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":50,"alternative-id":["10.3389\/fphar.2024.1441383"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1441383","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"article-number":"1441383"}}